InMed Pharmaceuticals Inc

ADAR1 Capital Fuels InMed Surge Ahead of Mentari Merger, Investors Eye Potential Breakout ?

ADAR1 Capital’s May 2026 buy‑spree of 468,551 InMed shares shows bullish confidence in its merger with Mentari and a potential surge in migraine‑therapy value.

InMed Pharmaceuticals Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

21/05/2026, 23:31

3 minutes to read

ADAR1 Capital and Executives Buy InMed Shares as Merger Buzz Builds: Is the Stock Poised for a Resurgence?

ADAR1 Capital’s new 331,449‑share stake in InMed Pharmaceuticals signals rising confidence amid a Mentari merger, offering a potential low‑price entry for biotech investors.

InMed Pharmaceuticals Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

21/05/2026, 23:15

3 minutes to read